 |
|
Update on Antiplatelet Therapy for Stroke Prevention
Ralph L. Sacco, MD;
Mitchell S. Elkind, MD
Arch Intern Med. 2000;160:1579-1582.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
The high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor management is effective for individuals with preclinical and clinical cerebrovascular disease. Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Prevention Study,1 the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment-related adverse effects. This combination is currently recommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke.
Stroke has a . . . [Full Text of this Article]
RISK OF STROKE AFTER A FIRST TIA OR STROKE
EFFICACY OF ANTIPLATELET AGENTS IN CLINICAL TRIALS
EVIDENCE FOR EFFICACY OF LOW-DOSE ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE: THE ESPS-2 TRIAL
NEW PRESCRIBING HABITS ARE RECOMMENDED
From the Department of Neurology and Public Health (Epidemiology), the Sergievsky Center, and the Neurological Institute, College of Physicians and Surgeons of Columbia University, and the New York Presbyterian Hospital, New York, NY.
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(11):1708-1709.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Improved Quality of Stroke Care for Hospitalized Medicare Beneficiaries in Michigan
Jacobs et al.
Stroke 2005;36:1227-1231.
ABSTRACT
| FULL TEXT
Current Strategies of Secondary Prevention After a Cerebrovascular Event: The Vienna Stroke Registry
Lalouschek et al.
Stroke 2001;32:2860-2866.
ABSTRACT
| FULL TEXT
Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome
Ruiz-Irastorza et al.
Lupus 2001;10:241-245.
ABSTRACT
Antiplatelet Therapy for Stroke Prevention
Journal Watch Cardiology 2000;2000:11-11.
FULL TEXT
Antiplatelet Therapy for Stroke Prevention
JWatch Neurology 2000;2000:2-2.
FULL TEXT
|
